Business UpdateJun 1, 2026, 04:05 PM
Fulcrum Discontinues Pociredir Program; Explores Strategic Alternatives
AI Summary
Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease (SCD) following FDA feedback. The FDA raised concerns about potential malignancy risk associated with PRC2 complex inhibition, citing issues with Tazverik®, another PRC2 inhibitor that was globally withdrawn. Despite pociredir showing robust elevations in fetal hemoglobin and being well-tolerated, the FDA's stance left no viable regulatory path. Consequently, Fulcrum will explore strategic alternatives to maximize stockholder value and is reducing operating expenses.
Key Highlights
- Fulcrum discontinued its pociredir program for sickle cell disease (SCD).
- Decision follows FDA feedback regarding malignancy risk with PRC2 inhibitors.
- FDA cited the global withdrawal of Tazverik® (tazemetostat) in March 2026.
- Company will explore strategic alternatives to maximize stockholder value.
- Fulcrum initiated efforts to significantly reduce operating expenses.
- Cash, cash equivalents, and marketable securities were $333.3 million as of March 31, 2026.
Price Impact
More from FULC